Blueprint Medicines (BPMC)
(Delayed Data from NSDQ)
$106.70 USD
-1.64 (-1.51%)
Updated May 10, 2024 04:00 PM ET
After-Market: $106.66 -0.04 (-0.04%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Blueprint Medicines (BPMC) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$116.53 | $168.00 | $75.00 | 7.56% |
Price Target
Based on short-term price targets offered by 15 analysts, the average price target for Blueprint Medicines comes to $116.53. The forecasts range from a low of $75.00 to a high of $168.00. The average price target represents an increase of 7.56% from the last closing price of $108.34.
Analyst Price Targets (15)
Broker Rating
Blueprint Medicines currently has an average brokerage recommendation (ABR) of 1.81 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 16 brokerage firms. The current ABR compares to an ABR of 1.94 a month ago based on 16 recommendations.
Of the 16 recommendations deriving the current ABR, 10 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 62.5% and 6.25% of all recommendations. A month ago, Strong Buy made up 62.5%, while Buy represented 6.25%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 10 | 10 | 10 | 10 | 11 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 4 | 3 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 1 | 2 | 2 | 2 | 2 |
ABR | 1.81 | 1.94 | 1.94 | 1.94 | 1.88 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/6/2024 | SVB Securities | Andrew Berens | Strong Sell | Hold |
5/3/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/26/2024 | Needham & Company | Ami Fadia | Moderate Buy | Moderate Buy |
4/26/2024 | H.C. Wainwright & Co. | Andrew S Fein | Strong Buy | Strong Buy |
4/26/2024 | Wedbush Securities | David M Nierengarten | Strong Buy | Strong Buy |
4/22/2024 | Piper Sandler | Christopher Raymond | Hold | Hold |
4/10/2024 | JMP Securities | Reni Benjamin | Strong Buy | Strong Buy |
2/29/2024 | Guggenheim Securities | Michael Schmidt | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.81 |
ABR (Last week) | 1.94 |
# of Recs in ABR | 16 |
Average Target Price | $116.53 |
LT Growth Rate | 34.00% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 84 of 252 |
Current Quarter EPS Est: | -1.28 |